# EDGAR Filing Document

**Accession Number:** 0001681087
**File Stem:** 0000000000-25-007282
**Filing Date:** 2025-7
**Character Count:** 2416
**Document Hash:** b43e378786e248dd95649b42c29a22d7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007282.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0000000000-25-007282

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250710

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tectonic Therapeutic, Inc.
- **CENTRAL INDEX KEY:** 0001681087
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 810710585
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-288539

**BUSINESS ADDRESS:**
- **STREET 1:** 490 ARSENAL WAY
- **STREET 2:** SUITE 210
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** (339) 666-3320

**MAIL ADDRESS:**
- **STREET 1:** 490 ARSENAL WAY
- **STREET 2:** SUITE 210
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AVROBIO, Inc.
- **DATE OF NAME CHANGE:** 20180131

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AvroBio, Inc.
- **DATE OF NAME CHANGE:** 20160729
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-25-156183

## Text-Extract

```

                                                           July 10, 2025

Daniel Lochner
Chief Financial Officer
Tectonic Therapeutic, Inc.
490 Arsenal Way
Suite 210
Watertown, MA 02472

        Re: Tectonic Therapeutic, Inc.
            Registration Statement on Form S-3
            Filed July 7, 2025
            File No. 333-288539
Dear Daniel Lochner:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Jessica Dickerson at 202-551-8013 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Brandon Fenn, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._